Novo Nordisk launches multi-month Wegovy subscriptions for cash-paying patients

Novo Nordisk on March 31, 2026 launched its first multi-month subscription program for Wegovy (semaglutide), aimed at patients who pay for the drug themselves. The company says the plans cut costs by up to $1,200 a year on the injection and up to $600 a year on the pill compared with paying for each month separately ^[2][3].

The program opened Tuesday through the telehealth providers Ro, WeightWatchers and LifeMD, with Hims & Hers, Sesame and others expected to join soon ^[2][3]. Eligible self-pay patients choose a three-, six- or 12-month subscription, and longer plans carry lower monthly prices ^[3]. Novo said patients pay a flat monthly rate even if they move to a different dose, and that they can opt out while a subscription is active ^[2].

For the Wegovy injection, prices are $329 a month for three months, $299 for six months and $249 for 12 months. Novo lists those as annual savings of $240, $600 and $1,200 versus paying month to month ^[3]. Reuters described the range as roughly 6% to 29% below Wegovy's standard $349 monthly self-pay price ^[4]. Novo's announcement lists the covered strengths as 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg ^[3]; CNBC reported the covered strengths as 0.25 mg, 0.5 mg, 1.7 mg and 2.4 mg ^[2].

For the Wegovy pill, the subscriptions cover the 9 mg and 25 mg doses at $289 a month for three months, $269 for six months and $249 for 12 months, which Novo lists as savings of $120, $360 and $600 a year ^[3]. Reuters put that at about 3% to 17% below the pill's standard $299 monthly self-pay price ^[4].

The lower pill doses are not part of the subscriptions. Self-pay patients pay $149 a month for the 1.5 mg and 4 mg doses, and the 4 mg price rises to $199 a month after August 31, 2026, according to Novo ^[3]. The 7.2 mg Wegovy HD injection, which the FDA approved on March 19, 2026 ^[1], will be added to the subscription program later, and no date has been disclosed ^[2][3].

"The new Wegovy subscription program removes barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment," said Ed Cinca, Novo Nordisk's senior vice president of marketing and patient solutions ^[3]. In a separate interview, Cinca said patients can opt out while enrolled and that Novo is not yet offering the program through its NovoCare direct-to-consumer pharmacy but may build it out there later ^[2].

Novo is trying to hold ground in a market where Eli Lilly is the dominant branded GLP-1 seller, with an estimated 60% share against Novo's roughly 39% ^[2]. Lilly's self-pay prices for Zepbound start at $299 a month for the 2.5 mg dose and rise to $449 for 7.5 mg and higher doses, Reuters reported ^[4]. Lilly's rival oral obesity drug is under FDA review, with approval expected in the second quarter and possibly in April ^[4]. Novo's move also targets a longstanding problem: one 2025 study estimated that about 65% of patients with obesity stop GLP-1 treatment within a year ^[2].

Why it matters for patients

Wegovy injection has carried a standard self-pay price of $349 a month, and the pill $299 a month ^[4]. The subscriptions lower the monthly figure for people who pay cash and commit to several months, and they make the cost the same from month to month rather than changing with the dose ^[2]. That predictability is the stated goal: Novo says the program is meant to reduce cost uncertainty and support staying on treatment ^[3].

Whether the subscriptions are cheaper than a patient's other options depends on their situation. Novo says people with commercial insurance coverage can still get Wegovy for as little as $25 a month through existing savings programs, and that the drug is available at more than 70,000 US pharmacies and through NovoCare Pharmacy ^[3]. Terms and eligibility vary by telehealth platform, and Novo directs patients to their telehealth provider for details ^[3]. Patients who use the lower pill doses are not covered by the subscription tiers, and the 4 mg dose becomes more expensive after August 31, 2026 ^[3].

What happens next

Hims & Hers, Sesame and other telehealth providers are expected to be added to the program soon, with no date given ^[2][3]. Novo has said the 7.2 mg Wegovy HD injection will join the subscription program at a later, undisclosed date ^[2][3]. The 4 mg Wegovy pill moves from $149 to $199 a month after August 31, 2026 ^[3]. Lilly expects an FDA decision on its oral obesity drug in the second quarter of 2026, possibly in April ^[4].